EC Number   |
Application |
Reference |
|---|
    1.3.1.24 | more |
interacts with the insulin receptor kinase domain, key factor in the MAPK pathway and the PI3K pathway as well as regulating PKC isoforms that link the two pathways, plays a role in the mechanism of insulin resistance |
676353 |
| 1.3.1.24 | more |
potential function in propagation of signals relayed through protein kinase C, binds to protein kinase C betaII, increases its phosphorylation, and is a substrate for the kinase, increases PMA-dependent c-fos activation and protein kinase C translocation to the membrane |
674899 |
| 1.3.1.24 | more |
potential role in the insulin signaling pathway, BVR is both a substrate for insulin receptor tyrosine kinase activity and a kinase for serine phosphorylation of insulin receptor substrate 1 |
666747 |
| 1.3.1.24 | more |
regulates oxidative response and HO-1 expression |
676353 |
| 1.3.1.24 | pharmacology |
critical role for biliverdin reductase A in protecting against lipid accumulation and oxidative stress in hepatocytes which may serve as a future therapeutic target for non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH) |
762673 |
| 1.3.1.24 | pharmacology |
transduced fusion protein Tat-biliverdin reductase A (Tat-BLVRA) markedly inhibits cell death, DNA fragmentation, and generation of ROS. Transduced Tat-BLVRA inhibits the apoptosis and mitogen activated protein kinase (MAPK) signaling pathway and it passes through the blood-brain barrier (BBB) and significantly prevents hippocampal cell death in an ischemic model. Tat-BLVRA provides a possibility as a therapeutic molecule for ischemia |
763156 |
